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Abstract
The recent publication of the Schistosoma japonicum and S. mansoni genomes has expanded greatly the opportu-
nities for post-genomic schistosomiasis vaccine research. Immunomics protein microarrays provide an excellent
application of this new schistosome sequence information, having been utilised successfully for vaccine antigen
discovery with a range of bacterial and viral pathogens, and malaria.
Accordingly, we have designed and manufactured a Schistosoma immunomics protein microarray as a vaccine dis-
covery tool. The microarray protein selection combined previously published data and in silico screening of avail-
able sequences for potential immunogens based on protein location, homology to known protective antigens, and
high specificity to schistosome species. Following cloning, selected sequences were expressed cell-free and con-
tact-printed onto nitrocellulose microarrays. The reactivity of microarray proteins with antisera from schistosomiasis-
exposed/resistant animals or human patients can be measured with labelled secondary antibodies and a laser
microarray scanner; highly reactive proteins can be further assessed as putative vaccines. This highly innovative
technology has the potential to transform vaccine research for schistosomiasis and other parasitic diseases of
humans and animals.
Review
Schistosomiasis causes significant morbidity and mortal-
ity in the developing world with recent studies indicat-
ing that the geographic extent and burden of the disease
exceeds official estimates [1]. Praziquantel-based che-
motherapy has achieved some success in controlling the
disease but is not an optimal strategy due to its inade-
quate impact on reducing long-term transmission [1].
Despite the mass chemotherapy programs, schistosome
reinfection rates and prevalence continue to be unaccep-
tably high, with rebound prevalence and morbidity an
inevitable consequence if ongoing interventions are not
sustained [2,3]. Along with other options, long-term
protection afforded by vaccination will be necessary for
the future control and possible elimination of schistoso-
miasis. The currently available vaccine antigens were
discovered empirically using attenuated schistosome lar-
vae, protective monoclonal antibodies, or by analysis of
human antibody and cytokine responses to recombi-
nantly-derived proteins [4]. These identified vaccine
molecules may, however, lack the required efficacy
because: 1) the vaccine-induced protective immunity
generated in animal models may not translate to
humans; 2) there is uncertainty about the type of
human response most appropriate for protective immu-
nity; and 3) the antigens may not be expressed on the
schistosome apical surface, and will not therefore be
exposed to the host immune system [2,4].
Key to the identification of new target vaccine mole-
cules and high throughput antigen discovery are the
recently published complete genomes of Schistosoma
japonicum and S. mansoni [5,6], and related post-geno-
mic research on the schistosome proteome, transcrip-
tome, glycome and immunome [7,8]. The amalgamation
of the information provided by these data sets, together
with consideration of the host-parasite immune
response in the field of immunomics, promises to result
in more rapid and promising antigen discovery and the
development of an effective vaccine for schistosomiasis
[9-11].
Conventional proteomic studies on schistosomes iden-
tified proteins from male and female worms, different
life-cycle stages, and parasite fractions and excretions
that were separated by one or two dimensional (1/2D)
gel electrophoresis (GE) and/or liquid chromatography
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on the schistosome surface can be further characterised
using biotinylated reagents, infection sera and/or by
enzymatic stripping [12]. For example, 71 sero-reactive
adult S. haematobium worm antigens were identified
using 2D GE of soluble parasite fractions, labelling with
resistant human sera, and identification by MS [13].
However, due to the limitations of MS detection and
protein extract preparation and separation, often only
the most abundant cytosolic and possibly least immuno-
logically meaningful proteins can be identified by this
procedure [7,12]. An immunomics protein microarray
p r o v i d e sac o n v e n i e n tm e t h o dt h a ta v o i d ss o m eo ft h e
limitations inherent in other proteomic approaches but
allows profiling of the host immune response to parasite
antigens in a high throughput manner.
Since the first application of immunomics for vaccine
discovery, antigens for ten microbial pathogens have now
entered clinical or preclinical development [9]. Immu-
nomics-based approaches typically combine in silico gen-
ome screening followed by high throughput protein
expression, and purification and immunological testing
of selected proteins [9]. The genome mining techniques
include reverse vaccinology and epitope mapping, i.e. the
prediction of potential virulence factors or secreted/sur-
face proteins, and immunogenic T- or B-cell epitopes
[9,10,14]. A further modification to the immunomics
selection process is the incorporation of comparative or
pan-genomics, and structural-genomics [9,11].
An immunomics approach has not hitherto been uti-
lised in schistosome (or any other metazoan parasite)
antigen discovery. Consequently, with collaborators at
the University of California, Irvine (UCI), we have used
a previously published strategy [15] to design and con-
struct a Schistosoma protein microarray for the identifi-
cation of novel anti-schistosome vaccine candidates. The
design, manufacture and probing of the microarray is
illustrated in Figure 1.
As proof-of-concept for the approach, a subset of
potentially immunogenic open reading frames (ORFs)
were selected for expression and printing from publi-
cally available coding sequences for S. japonicum (214
selected) and S. mansoni (63 selected). These sequences
were chosen from bioinformatic, proteomic and tran-
scriptomic data using the following criteria: high
sequence homology among the two schistosome species;
expression in the immunologically vulnerable schistoso-
mulum larval stage; predicted or known to be localised
on the parasite surface; and limited sequence similarity
with mammalian homologues (Figure 2). In addition, S.
japonicum homologues of S. mansoni vaccine candidates
and surface proteins (30 ORFs) were also selected as
were a large proportion of hypothetical and proteomi-
cally uncharacterised proteins (77 ORFs). Primers were
designed with 20 base pairs specific to each transcript
and 20 base pairs specific to the expression vector (5’-
ACGACAAGCATATGCTCGAG; 3’ -A T T A A C C T -
TATGAAAATATT). Sequences were PCR-amplified
Figure 1 Design, construction and probing of the Schistosoma immunomics protein microarray.
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into the pXi T7 bacterial vector by homologous recom-
bination. Of the sequences, 88% (244) were able to be
PCR- amplified and these resultant plasmids were puri-
fied, and the inserts verified by PCR and by sequencing.
A total of 222 (80%) high-yielding plasmids with cor-
rect inserts were expressed in an in vitro cell-free
Escherichia coli system (Roche RTS 100), and the pro-
tein extracts contact-printed without purification onto
nitrocellulose glass FAST® slides. In addition, known S.
japonicum and S. mansoni recombinant antigens (serial
d i l u t i o n so f1 7c o n s t r u c t si ncluding tetraspanins,
annexins, Sm29, Sj29, and expression tags alone)
expressed in E. coli or Pichia pastoris were printed in
each microarray. Controls on the microarray included
nine no-DNA negative controls -in vitro expression
solution without plasmid template, three PBS only
controls, and positive controls (four serial dilutions of:
pooled human, mouse, guinea pig, goat, cat and
chicken IgG antibodies, Jackson ImmunoResearch; and
the EBNA1 protein of Epstein-Barr virus). The printed
in vitro expressed proteins were quality checked using
antibodies against incorporated N-terminal poly-histi-
dine (His) and C-terminal hemaglutinin (HA) tags
(Figure 3A &3B), and showed high protein expression
efficiency. The printed protein microarray is amenable
to probing with anti-sera, pre-treated with E. coli
lysate, to prevent non-specific binding of immunoglo-
bulins to bacterial proteins on the microarray. Serolo-
gical reactivity is determined using fluorophore-
labelled secondary antibodies and detected using a
laser array scanner. The signal intensities are trans-
formed and normalised using the vsn statistical pack-
age http://www.r-project.org and the background
signal determined from the average of the no-DNA
controls within each microarray. Positive signal inten-
sity is defined as two standard deviations above the
background signal [16]. Preliminary probing of the
schistosome immunomics protein microarray with
pooled sera from Swiss mice infected for 7 weeks with
S. japonicum (Figure 3C), S. mansoni (Figure 3D), and
naïve mouse sera (Figure 3E) is shown, demonstrating
specific recognition of schistosome antigens by the
murine host. The recognised antigens are a combina-
tion of in vitro-expressed hypothetical, surface and
structural proteins as well as recombinant antigens
expressed in bacteria and yeast. It is noteworthy that
our preliminary analysis indicates some antigens are
c o m m o n l yr e a c t i v ew i t hs e r af r o mm i c ei n f e c t e dw i t h
either S. japonicum or S. mansoni. This approach can
be readily extended for the identification of putative
anti-schistosome vaccine targets using resistant versus
susceptible infection sera from animal models and/or
humans from endemic areas, subsequent to preclinical
vaccine efficacy studies.
This protein microarray technology platform has been
now applied to over 30 pathogens including viruses,
bacteria and protists (e.g. [17]). The approach allows
efficient expression of putative antigens without many of
the problems of conventional protein expression and
p u r i f i c a t i o n .T h i si se x e m p l i f i e db yPlasmodium
Figure 2 Composition of the proof-of-concept schistosome
protein microarray. Red circle, tegumental/surface/signal peptide/
membrane proteins from various stages; blue circle, proteins specific
to Schistosoma species; and yellow circle, proteins specific to
schistosomula.
Figure 3 Probing of the schistosome protein microarray. The protein microarray includes cell-free S. japonicum (Sj) and S. mansoni (Sm)
proteins as well as known recombinant antigens (RA) that were expressed conventionally in vivo in bacteria and yeast. The protein microarray
was probed with monoclonal antibodies against the N-terminal poly-histidine tag (A) and C-terminal hemagglutinin tag (B); with pooled sera
from Swiss outbred mice after a 7 week infection with S. japonicum (C); S. mansoni (D); and naïve mouse serum (E).
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using bacteria, yeast, insect cells as well as the wheat
germ cell-free system results in very low expression effi-
ciency because of its rare codon usage and high A + T
content. However, using a similar platform to the Schis-
tosoma protein microarray described here, >93% expres-
sion efficiency was achieved for a similar proof-of-
concept study of 250 P. falciparum proteins with 14 new
potential vaccine targets being identified [18].
Compared with conventional proteomics approaches,
an immunomics protein microarray can efficiently
express many more potential antigens that are selected
using known or predicted surface location and are read-
ily identified after serological screening. A comparison
of the characteristics of proteomics approaches with
immunomics protein microarrays is presented in Table
1. Immunomics provides a powerful addition to antigen
discovery, but the technology does have some drawbacks
summarised in Appendix 1. For example, proteins
expressed by the E. coli cell-free system may lose some
post-translational modifications and tertiary protein
structure [18]. Further, different microarray antigens
cannot be compared with each other and protein levels
within each microarray feature are difficult to quantify
[16].
Nevertheless, this antigen discovery approach will be
readily adaptable to other parasites as more genome
sequence information and post-genomic data become
available. We anticipate that such microarray platforms
will facilitate the identification of novel vaccine candi-
dates that may not have been revealed using conven-
tional methodologies, thereby providing a valuable
approach for vaccine discovery.
Appendix 1
Advantages and disadvantages of immunomics protein
microarray technology.
Advantages
Proteome-wide, selective expression of full-length pro-
teins including insoluble and membrane proteins
Protein expression can be determined from C- and N-
terminal tags
High throughput screening of antibody responses from
experimentally immunized or naturally exposed indivi-
duals and animal models
Small serum sample volume (1 microliter) required for
immunoscreening
Disadvantages
Some loss of protein tertiary structure and post-transla-
tional modifications
Reactivity is not directly comparable between microarray
antigens
Microarray protein levels cannot be quantified
Antibodies against E. coli proteins in cell-free extract
must be blocked
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